INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients
AAIC Poster Presentation Highlights XPro’s™ Significant Effects on a Wide Range of Synaptic Proteins and Pathways
BOCA RATON, FL, USA I July 29, 2024 IINmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease is pleased to be presenting results of a new and advanced proteomic analysis at this year’s annual Alzheimer’s Association International Conference (AAIC) in Philadelphia, PA. The poster summarizes dose-related changes in the cerebrospinal fluid (CSF) proteome in patients with Alzheimer’s disease (AD) treated with XProTM in the company’s phase 1b study.
Monday, July 29
Poster #95343
Dose-related modulation of the synaptic proteome after short-term treatment with XPro1595 for Alzheimer’s disease
The new analysis revealed that a 12-week treatment with XPro™ resulted in a significant change in synaptic proteins, which are essential for communication between neurons.
“The loss of synapses begins early in Alzheimer’s disease and has devastating consequences as the disease progresses,” stated CJ Barnum, PhD, VP of Neuroscience at INmune Bio. “The robust effect of XProTM on a broad number of proteins and pathways that regulate the formation of synapses is consistent with what we have observed in preclinical models and what we expect to happen when normal/healthy immune function is restored.”
The formation and elimination of synapses is executed by cells of the innate immune system such as astrocytes. When these cells are in a dysregulated inflammatory/immune state, synapse formation is reduced and synapse elimination is increased, resulting in loss of communication between neurons which, in the case of AD, results in cognitive impairment. Restoring synapses requires a normally functioning innate immune system.
“We are encouraged by this new evidence of a treatment effect at the cellular level in proteins known to be affected by AD pathologies,” said Company CEO RJ Tesi, MD. “XPro’s direct impact on synaptic proteins provides further support to the improvement in synaptic function we recently observed with EEG data and provides further evidence that we are having a significant effect on restoring the immune system. This is yet another biological precursor to what we believe will result in a cognitive benefit which we are currently testing in our ongoing Phase 2 trial.”
INmune Bio is currently running a phase 2 clinical trial in mild to moderate Alzheimer’s patients. Top-line results from that trial are expected in early 2025.
AboutXPro™
XPro™ is a next-generation inhibitor of tumor necrosis factor (TNF) that is currently in clinical trial and acts differently than currently available TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro™ could have potential substantial beneficial effects in patients with neurologic disease by decreasing neuroinflammation without immunosuppression. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit thissectionoftheINmuneBio’swebsite.
About INmune Bio Inc.
INmuneBioInc. is a publicly traded (NASDAQ: INMB), clinical-stage inflammation and immunology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™), Early Alzheimer’s disease and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com.
AAIC Poster Presentation Highlights XPro’s™ Significant Effects on a Wide Range of Synaptic Proteins and Pathways
BOCA RATON, FL, USA I July 29, 2024 IINmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease is pleased to be presenting results of a new and advanced proteomic analysis at this year’s annual Alzheimer’s Association International Conference (AAIC) in Philadelphia, PA. The poster summarizes dose-related changes in the cerebrospinal fluid (CSF) proteome in patients with Alzheimer’s disease (AD) treated with XProTM in the company’s phase 1b study.
Monday, July 29
Poster #95343
Dose-related modulation of the synaptic proteome after short-term treatment with XPro1595 for Alzheimer’s disease
The new analysis revealed that a 12-week treatment with XPro™ resulted in a significant change in synaptic proteins, which are essential for communication between neurons.
“The loss of synapses begins early in Alzheimer’s disease and has devastating consequences as the disease progresses,” stated CJ Barnum, PhD, VP of Neuroscience at INmune Bio. “The robust effect of XProTM on a broad number of proteins and pathways that regulate the formation of synapses is consistent with what we have observed in preclinical models and what we expect to happen when normal/healthy immune function is restored.”
The formation and elimination of synapses is executed by cells of the innate immune system such as astrocytes. When these cells are in a dysregulated inflammatory/immune state, synapse formation is reduced and synapse elimination is increased, resulting in loss of communication between neurons which, in the case of AD, results in cognitive impairment. Restoring synapses requires a normally functioning innate immune system.
“We are encouraged by this new evidence of a treatment effect at the cellular level in proteins known to be affected by AD pathologies,” said Company CEO RJ Tesi, MD. “XPro’s direct impact on synaptic proteins provides further support to the improvement in synaptic function we recently observed with EEG data and provides further evidence that we are having a significant effect on restoring the immune system. This is yet another biological precursor to what we believe will result in a cognitive benefit which we are currently testing in our ongoing Phase 2 trial.”
INmune Bio is currently running a phase 2 clinical trial in mild to moderate Alzheimer’s patients. Top-line results from that trial are expected in early 2025.
AboutXPro™
XPro™ is a next-generation inhibitor of tumor necrosis factor (TNF) that is currently in clinical trial and acts differently than currently available TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro™ could have potential substantial beneficial effects in patients with neurologic disease by decreasing neuroinflammation without immunosuppression. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit thissectionoftheINmuneBio’swebsite.
About INmune Bio Inc.
INmuneBioInc. is a publicly traded (NASDAQ: INMB), clinical-stage inflammation and immunology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™), Early Alzheimer’s disease and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com.
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
